Link: Cubist shares dive on sales results.
Goldman Sachs analyst Meg Malloy reaffirmed a "Neutral" rating with a $26 price target, saying Cubicin sales results matched Goldman Sachs’ forecast, but the earnings per share missed on slightly higher operating expenses. She also maintained forecasts for the next several years.
"We continue to believe Cubicin is in the relatively early stages of a steady growth trajectory, driven by unmet medical need and strong clinical data in MRSA (staph) infection," she wrote in a note to investors. "We anticipate growth from label expansions, increasing penetration into the outpatient setting and international expansion."
